MELANOMA S2000

Study #S2000

A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF V600-Mutant Melanoma with Brain Metastases

Back To Clinical Trials